Neteera Overview
Neteera enhances patient care through a contactless monitoring solution that delivers vital and activity metrics. Its CE MDR & FDA-approved technology, designed for hospitals, post-acute and home care, features a smart sensing platform that requires no device manipulation or clothing removal. Powered by a maintenance-free micro-radar chip, Neteera provides real-time patient data. With customizable alerts for healthcare staff, including threshold deviations, Neteera enables teams to proactively address patient conditions. Simple, accurate, and secure - Neteera empowers healthcare providers and enhances the patient experience.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Neteera raises an additional $6.7M Series B Extension
Neteera Technologies Ltd., an Israeli-based startup, has announced the successful closing of a ~$6.7M Series B extension. The round was led by Aescuvest, a healthcare investment firm, and Foxconn Technology Co., Ltd. The funds will be used to expedite production, meet increasing demand for Neteeras platform, and recruit more installation and deployment personnel. The partnership with Foxconn Technology Group will boost Neteeras international growth. Neteeras FDA-cleared remote patient monitoring platform is improving patient care and operator efficiencies globally.
InvestmentPartnersExpand
growth-positive
Healthtech startup Neteera secures $13 million Series B for contactless patient monitoring | CTech
Israeli-based startup Neteera Technologies has closed a $13 million Series B funding round led by Aescuvest and including Omega Healthcare Investors. The company has also entered into a strategic partnership with Omega to offer its contactless remote patient monitoring technology to Omegas healthcare operating partners. Neteeras technology enables continuous monitoring of patients bio markers without the need for contact or patient involvement, improving outcomes and reducing the burden on clinical staff. The funding and partnership will help Neteera expand its reach and accelerate its mission to improve patient outcomes. Omega deployed Neteeras technology across a test group of facilities and received positive feedback, with a reduction in hospitalizations and early recognition of changes in resident clinical needs.
InvestmentPartners
growth-positive
Neteera makes annual CNBC Disruptor 50 list second year running
Neteera, a global leader in contactless vital signs sensing, has been named to the CNBC Disruptor 50 for the second year in a row. The Jerusalem-based startup has developed a contact-free microsensor that can monitor human physiological parameters in real time. The technology is suitable for use in homes, hospitals, and care facilities, enabling personalized care worldwide. Neteeras inclusion in the CNBC Disruptor 50 list highlights its potential to transform healthcare. The company aims to make healthcare available to all and improve patient care while saving costs for healthcare systems. Neteeras technology is based on proprietary micro-radar on chip, algorithms, artificial intelligence, and cloud. The company has been recognized for its innovation and contribution to the healthcare industry.
CustomersExpand
growth-positive
CNBC Names Contactless Vitals Startup Neteera to Disruptor 50 List
Neteera, a global leader in contactless vital signs sensing, has been ranked ninth in CNBCs annual Disruptor 50 list. Their revolutionary sensing technology allows for continuous, contactless, and clinical grade monitoring of human vital signs. The technology is used in hospitals, care facilities, and public venues to indicate potential COVID-19 patients. Neteeras solution reduces the risk of cross contamination and is reshaping healthcare delivery. The company is honored to be recognized and is committed to bringing safety, comfort, quality, and equality of care to all in need.
CustomersPartners
growth-positive
Neteera, the Global Leader in Contact-free Vital Signs Monitoring, Launches Contactless Vital Signs Sensing System for COVID-19 Early Screening and Home Care
Jerusalem-based startup Neteera has accelerated the production schedule of its first-generation commercial platform, the Neteera Contactless Vitals series (NCV), in response to the COVID-19 crisis. The platform includes the Neteera-1.0 Contactless Screening, which detects elevated heart rate, breathing rate, and temperature for first-line screening, and the Neteera-1.2 Contactless Vitals Sensor, which enables continuous contactless monitoring of vital signs. Neteera is collaborating with governmental and corporate healthcare bodies in Israel and abroad. The companys technology uses a proprietary high-resolution radar on chip and patented software to remotely and contactlessly monitor human vital signs, reducing physical contact and the risk of healthcare-associated infections. Neteera is experiencing growth-positive impact due to the increased demand for its remote vital signs monitoring solutions.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $36.4M |
| Last funding | $6.7M |
| Stage | B |
| Rounds | 5 |
| Investors | 8 |
Team Members
8
Employees: 51-200
Web & Social Links
| Website | www.neteera.com |
| Careers | Careers page |
Locations
Givat Ram, Jerusalem, Israel
Delaware, USA
Photos & Videos
2 item(s)
